Day One Biopharmaceuticals, Inc. DAWN
We take great care to ensure that the data presented and summarized in this overview for Day One Biopharmaceuticals, Inc. is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding DAWN
View all-
Atlas Venture Life Science Advisors, LLC6.43MShares$46.4 Million14.93% of portfolio
-
Vanguard Group Inc Valley Forge, PA5.94MShares$42.9 Million0.0% of portfolio
-
Ra Capital Management, L.P. Boston, MA5.76MShares$41.5 Million0.95% of portfolio
-
Black Rock Inc. New York, NY4.53MShares$32.7 Million0.0% of portfolio
-
Alyeska Investment Group, L.P. Chicago, IL4.06MShares$29.3 Million0.14% of portfolio
-
Franklin Resources Inc San Mateo, CA4.02MShares$29 Million0.01% of portfolio
-
Pictet Asset Management Holding Sa Carouge, V83.64MShares$26.2 Million0.03% of portfolio
-
Braidwell LP Stamford, CT3.54MShares$25.5 Million1.72% of portfolio
-
Estuary Capital Management LP Wayzata, MN3.33MShares$24 Million6.4% of portfolio
-
Deerfield Management Company, L.P. (Series C) New York, NY2.96MShares$21.3 Million0.59% of portfolio
Latest Institutional Activity in DAWN
Top Purchases
Top Sells
About DAWN
Day One Biopharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops and commercializes targeted therapies for patients with genetically defined cancers. Its lead product candidate is DAY101, an oral brain-penetrant type II pan-rapidly accelerated fibrosarcoma kinase inhibitor that is in Phase II clinical trial for pediatric patients with relapsed/progressive low-grade glioma. The company is also developing Pimasertib, an oral small molecule inhibitor of mitogen-activated protein kinase kinases 1 and 2. Day One Biopharmaceuticals, Inc. was incorporated in 2018 and is headquartered in South San Francisco, California.
Insider Transactions at DAWN
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Jul 10
2025
|
Jeremy Bender CHIEF EXECUTIVE OFFICER |
BUY
Bona fide gift
|
Indirect |
402,057
+10.49%
|
-
|
|
Jul 10
2025
|
Jeremy Bender CHIEF EXECUTIVE OFFICER |
SELL
Bona fide gift
|
Indirect |
601,259
-76.55%
|
-
|
|
May 16
2025
|
Lauren Merendino Chief Commercial Officer |
SELL
Open market or private sale
|
Direct |
3,927
-10.05%
|
$23,562
$6.26 P/Share
|
|
May 16
2025
|
Charles N York Ii COO, CFO AND SECRETARY |
SELL
Open market or private sale
|
Direct |
4,282
-1.59%
|
$25,692
$6.26 P/Share
|
|
May 16
2025
|
Adam Dubow GENERAL COUNSEL |
SELL
Open market or private sale
|
Direct |
4,552
-8.81%
|
$27,312
$6.26 P/Share
|
|
May 16
2025
|
Jeremy Bender CHIEF EXECUTIVE OFFICER |
SELL
Open market or private sale
|
Direct |
13,964
-8.74%
|
$83,784
$6.26 P/Share
|
|
May 15
2025
|
Lauren Merendino Chief Commercial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
10,536
+9.04%
|
-
|
|
May 15
2025
|
Charles N York Ii COO, CFO AND SECRETARY |
BUY
Exercise of conversion of derivative security
|
Direct |
16,875
+1.57%
|
-
|
|
May 15
2025
|
Adam Dubow GENERAL COUNSEL |
BUY
Exercise of conversion of derivative security
|
Direct |
12,086
+6.02%
|
-
|
|
May 15
2025
|
Jeremy Bender CHIEF EXECUTIVE OFFICER |
BUY
Exercise of conversion of derivative security
|
Direct |
31,686
+5.03%
|
-
|
|
Feb 18
2025
|
Charles N York Ii COO, CFO AND SECRETARY |
SELL
Open market or private sale
|
Direct |
4,370
-1.7%
|
$48,070
$11.96 P/Share
|
|
Feb 18
2025
|
Jeremy Bender CHIEF EXECUTIVE OFFICER |
SELL
Open market or private sale
|
Direct |
12,048
-8.6%
|
$132,528
$11.96 P/Share
|
|
Feb 18
2025
|
Adam Dubow GENERAL COUNSEL |
SELL
Open market or private sale
|
Direct |
4,646
-10.5%
|
$51,106
$11.96 P/Share
|
|
Feb 15
2025
|
Charles N York Ii COO, CFO AND SECRETARY |
BUY
Exercise of conversion of derivative security
|
Direct |
16,875
+1.64%
|
-
|
|
Feb 15
2025
|
Jeremy Bender CHIEF EXECUTIVE OFFICER |
BUY
Exercise of conversion of derivative security
|
Direct |
31,686
+5.76%
|
-
|
|
Feb 15
2025
|
Adam Dubow GENERAL COUNSEL |
BUY
Exercise of conversion of derivative security
|
Direct |
12,086
+7.08%
|
-
|
|
Dec 10
2024
|
Samuel C. Blackman HEAD OF R&D |
SELL
Open market or private sale
|
Direct |
30,000
-2.82%
|
$390,000
$13.31 P/Share
|
|
Nov 18
2024
|
Jeremy Bender CHIEF EXECUTIVE OFFICER |
SELL
Open market or private sale
|
Direct |
10,554
-8.87%
|
$137,202
$13.21 P/Share
|
|
Nov 18
2024
|
Charles N York Ii COO, CFO AND SECRETARY |
SELL
Open market or private sale
|
Direct |
2,602
-1.07%
|
$33,826
$13.21 P/Share
|
|
Nov 18
2024
|
Adam Dubow GENERAL COUNSEL |
SELL
Open market or private sale
|
Direct |
3,165
-8.96%
|
$41,145
$13.21 P/Share
|
Last 12 Months Summary
| Exercise of conversion of derivative security | 226K shares |
|---|---|
| Bona fide gift | 402K shares |
| Open market or private sale | 185K shares |
|---|---|
| Bona fide gift | 601K shares |